An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial.

Norovirus is a leading cause of acute gastroenteritis globally, with infections in older adults associated with heightened severity and increased risk of mortality. Currently, no licensed vaccines are available to prevent norovirus infection. We developed an orally administered vaccine tablet (VXA-G1.